British CRO hVIVO reels in £16.8M clinical trial deal for RSV drug
13 Dec 2023
Phase 2Vaccine
Preview
Source: FierceBiotech
London-based CRO hVIVO inked a second contract in a year from an unnamed drugmaker to conduct clinical trials for a drug to treat respiratory syncytial virus (RSV).
London-based CRO hVIVO has landed a £16.8 million ($21 million) contract from an unnamed drugmaker to conduct a phase 2 trial of its respiratory syncytial virus (RSV) antiviral drug candidate.
The company, which hVIVO has only described as a “top five global pharmaceutical” organization, will use hVIVO’s human challenge study model. Additionally, the contract will see the expedited manufacture of the RSV challenge agent, as well as a confirmatory challenge cohort and a multiple cohort challenge trial, the company said in a Dec. 13 release.
HVIVO said it expects to start the RSV human challenge trial in the second half of 2024.
“Our RSV (Memphis strain) challenge agent has played a significant role in the development of RSV vaccines and we are delighted that it is continuing to be used as the go-to model for our clients,” CEO Yamin Khan said in the release.
In February, hVIVO, formerly known as Open Orphan, penned a £6.8 million ($8.2 million) deal with an unnamed pharmaceutical company to run a human challenge test for an RSV antiviral drug candidate. That study was scheduled to be conducted at hVIVO’s Whitechapel facility in London in the first half of 2024.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.